EZH2 and acute myeloid leukemia: An in vitro murine model demonstrated that there may be therapeutic utility in EZH2 inhibition (via GSK343 which is an S-adenosyl methionine-competitive inhibitor) in AML; EZH2 inhibition tested on primary human leukemia cells also demonstrated growth inhibition [138].